Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05936489 | Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia | PHASE1 | COMPLETED | 30 | — | — | Jul 6, 2023 | Oct 3, 2023 | Oct 16, 2023 | 1 | United States |
Maximum plasma concentrations of LNZ100 and LNZ101
Time of maximum plasma concentrations of LNZ100 and LNZ101
Area under the concentration-time curve from time 0 to time t of LNZ100 and LNZ100
Area under the concentration-time curve from time 0 to infinity of LNZ100 and LNZ101
Terminal half-life of LNZ100 and LNZ101
| Arm | Type | Description |
|---|---|---|
| LNZ101 | OTHER | Aceclidine 1.75% / Brimonidine combination (non-preserved) ophthalmic solution |
| LNZ100 | OTHER | Aceclidine 1.75% (non-preserved) ophthalmic solution |
| Name | Type | Description |
|---|---|---|
| Aceclidine + Brimonidine | DRUG | LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution |
| Aceclidine | DRUG | LNZ100 (Aceclidine) non-preserved ophthalmic solution |
Inclusion Criteria: * Each subject must: 1. Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed; 2. Be able and willing to follow all instructions and attend all study...